Developer · BHVN · United States
Biohaven Ltd.
Biohaven Ltd. (NYSE: BHVN) is a global clinical-stage biopharmaceutical company focused on therapies for neurological, neuropsychiatric, immunological, and oncological diseases. It is the spin-off entity that retained the non-CGRP pipeline after Pfizer acquired legacy Biohaven (Nurtec) in 2022.
Pipeline (4)
- EpilepsyPhase 3Recruiting
- Major depressive disorderDiscontinuedDiscontinued
- Bipolar disorderDiscontinuedDiscontinued
- Parkinson's diseasePhase 2/3Recruiting
- MigrainePhase 2Active
- Obsessive-compulsive disorderDiscontinuedDiscontinued
Deals & partnerships
- BHV-2100Licensor KU Leuven
- BHV-8000Licensor Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Opakalim (BHV-7000)Licensor Channel Biosciences, LLC (Knopp Biosciences)
- Troriluzole (BHV-4157)Licensor ALS Biopharma, LLC / Fox Chase Chemical Diversity Center
- Aug 26, 2026Licensing dealBiohaven licenses the Kv7 platform, led by opakalim (BHV-7000), to SK Biopharmaceuticals for up to $795MBiohaven Bioscience Ireland entered a license agreement granting SK Biopharmaceuticals an exclusive, royalty-bearing, worldwide license to the Kv7 ion channel platform led by opakalim (BHV-7000): $400M upfront ($350M at closing, $50M one year later), up to $150M in development/regulatory milestones, and tiered royalties from the mid-teens to low twenties on U.S. net sales. Opakalim remains in Phase 2/3 development for focal epilepsy (RISE3 topline expected 2H 2026).
- Mar 23, 2023Licensing dealBiohaven in-licenses dual TYK2/JAK1 inhibitor BHV-8000 from Hangzhou HighlightllExclusive license (global ex-China) to BHV-8000 (formerly TLL-041), an oral brain-penetrant dual TYK2/JAK1 inhibitor: $10M cash + $10M equity upfront, up to $950M milestones, tiered royalties.
- Feb 25, 2022AcquisitionBiohaven acquires Channel Biosciences' Kv7 platform (BHV-7000)Biohaven acquired Channel Biosciences (a Knopp Biosciences subsidiary) and its Kv7 (KCNQ2/3) ion-channel platform incl. BHV-7000 / opakalim (formerly KB-3061): $65M stock + $35M cash upfront, up to ~$325M epilepsy milestones plus further indication/commercial milestones and royalties.
- Jan 10, 2022Licensing dealBiohaven in-licenses TRPM3 antagonist platform (BHV-2100) from KU LeuvenExclusive global license and research collaboration for a small-molecule TRPM3 antagonist platform (lead BHV-2100) for pain, with undisclosed upfront/milestones plus mid-single-digit royalties.
- Aug 7, 2015Licensing dealBiohaven licenses troriluzole (BHV-4157) from ALS Biopharma / Fox ChaseBiohaven licensed troriluzole (BHV-4157), a tripeptide prodrug of riluzole, plus a portfolio of 300+ prodrugs from ALS Biopharma and Fox Chase Chemical Diversity Center (agreement dated Aug 7, 2015; amended May 29, 2019).
Catalysts · 2 upcoming · 8 reported
- 2H 2026Anticipated
Opakalim (BHV-7000)forEpilepsyTopline data
Top-line results expected from the first of two pivotal Phase 2/3 focal-epilepsy studies to support registration
- 2H 2027Anticipated
BHV-8000forParkinson's diseaseTopline data
Anticipated Phase 2/3 topline in early Parkinson's disease (primary endpoint: time to first qualifying worsening on MDS-UPDRS Part II)
Recently reported
- 2026-05-27met
Opakalim (BHV-7000)forEpilepsyInterim analysis
Opakalim focal-epilepsy open-label extension: ≥50% seizure reduction in 54% of six-month completers (75 mg QD)
- 2026-05-27met
Opakalim (BHV-7000)forEpilepsyTopline data
Opakalim IGE proof-of-concept topline: median time to 2nd generalized tonic-clonic seizure 141 vs 47 days (placebo)
- 2026-05-26terminated
Opakalim (BHV-7000)forEpilepsyInterim analysis
IGE proof-of-concept (SHINE) terminated early; ~3-fold prolongation in median time to second GTC seizure (141 vs 47 days), no formal statistics
- 2025-12-24missed
Opakalim (BHV-7000)forMajor depressive disorderTopline data
Phase 2 proof-of-concept MDD study of BHV-7000 misses MADRS primary endpoint; Biohaven exits psychiatric development
- 2025-08-11missed
Troriluzole (BHV-4157)forObsessive-compulsive disorderTopline data
Phase 3 OCD trial completed with no efficacy signal; Biohaven discontinues troriluzole in OCD.
- 2025-06-04missed
- 2025-03-03missed
Opakalim (BHV-7000)forBipolar disorderTopline data
Phase 2/3 bipolar mania study of BHV-7000 misses YMRS primary endpoint
- 2020-06-24missed
Troriluzole (BHV-4157)forObsessive-compulsive disorderTopline data
Phase 2/3 OCD proof-of-concept missed its Week-12 Y-BOCS primary endpoint (p=0.22).
Recent activity
- May 27, 2026ReadoutOpakalim (BHV-7000)·EpilepsymetOpakalim focal-epilepsy open-label extension: ≥50% seizure reduction in 54% of six-month completers (75 mg QD)source ↗
- May 27, 2026ReadoutOpakalim (BHV-7000)·EpilepsymetOpakalim IGE proof-of-concept topline: median time to 2nd generalized tonic-clonic seizure 141 vs 47 days (placebo)source ↗
- May 26, 2026ReadoutOpakalim (BHV-7000)·EpilepsyterminatedIGE proof-of-concept (SHINE) terminated early; ~3-fold prolongation in median time to second GTC seizure (141 vs 47 days), no formal statisticssource ↗
- Dec 24, 2025ReadoutOpakalim (BHV-7000)·Major depressive disordermissedPhase 2 proof-of-concept MDD study of BHV-7000 misses MADRS primary endpoint; Biohaven exits psychiatric developmentsource ↗
- Aug 11, 2025ReadoutTroriluzole (BHV-4157)·Obsessive-compulsive disordermissedPhase 3 OCD trial completed with no efficacy signal; Biohaven discontinues troriluzole in OCD.source ↗
- Jun 4, 2025ReadoutBHV-2100·MigrainemissedPhase 2 acute migraine trial of BHV-2100 detects no efficacy signal on the 2-hour pain-freedom and MBS co-primary endpointssource ↗
- May 28, 2025Phase changeBHV-8000·Parkinson's diseasePhase 2/3First patient enrolled in pivotal Phase 2/3 trial (NCT06976268) in early Parkinson's disease.source ↗
- Mar 24, 2025Phase changeBHV-2100·MigrainePhase 2NCT06603623 reached primary completion (CT.gov primary completion date 2025-03-24; overall status Completed) with 647 actual participants enrolled. Topline efficacy not yet publicly reported in primary sources as of 2025-05-12.source ↗
- Mar 3, 2025ReadoutOpakalim (BHV-7000)·Bipolar disordermissedPhase 2/3 bipolar mania study of BHV-7000 misses YMRS primary endpointsource ↗
- Oct 10, 2024Phase changeBHV-2100·MigrainePhase 2Biohaven initiated the pivotal Phase 2 acute migraine trial (NCT06603623); study start date 2024-10-10. Announced 2024-09-30 as ~575 patients across ~60 US sites at 75 mg and 150 mg vs placebo.source ↗
- May 28, 2024Phase changeOpakalim (BHV-7000)·Major depressive disorderPhase 2Phase 2 MDD monotherapy POC study (NCT06419608) started.source ↗
- May 28, 2024Phase changeOpakalim (BHV-7000)·Bipolar disorderPhase 2/3Phase 2/3 registrational acute bipolar mania study (NCT06419582) started; YMRS day-21 primary endpoint, BHV-7000 75 mg QD vs placebo, inpatient.source ↗
Trials recruiting · 3 recruiting of 10 sponsored
- Phase 2/3BHV-8000
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease
- Phase 2/3Opakalim (BHV-7000)
A Phase 2/3 Study to Evaluate Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
- Phase 2/3Opakalim (BHV-7000)
A Phase 2/3 Study to Evaluate Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Competitive landscape
Other companies developing against Biohaven Ltd.'s targets or indications.
- Cerevel Therapeutics Holdings, Inc.3 compoundsParkinson's diseaseEpilepsyMajor depressive disorder
- Intra-Cellular Therapies, Inc.2 compoundsParkinson's diseaseMajor depressive disorderBipolar disorder
- Xenon Pharmaceuticals Inc.1 compoundKv7.2EpilepsyMajor depressive disorder
- Neurocrine Biosciences, Inc.3 compoundsMajor depressive disorderBipolar disorder
- Tonix Pharmaceuticals Holding Corp.2 compoundsMigraineMajor depressive disorder
- Vanda Pharmaceuticals Inc.1 compoundMajor depressive disorderBipolar disorder
- Alto Neuroscience, Inc.2 compoundsMajor depressive disorder
- Alzamend Neuro, Inc.1 compoundBipolar disorder
- Autobahn Therapeutics, Inc.1 compoundMajor depressive disorder
- Axsome Therapeutics, Inc.1 compoundMajor depressive disorder
- Beckley Psytech Limited1 compoundMajor depressive disorder
- Boehringer Ingelheim2 compoundsMajor depressive disorder
